Key Takeaway: Ultragenyx reported a total revenue of $214 million for the second quarter of 2026, with Crysvita® contributing $156 million and Dojolvi® $27 million. The company reaffirmed its financial guidance for 2026, projecting total revenue between $730 million and $760 million. Additionally, it expects combined R&D and SG&A expenses to remain flat or slightly decrease compared to 2025.
Market Sentiment Analysis
POSITIVE FACTORS
Total revenue of $214 million indicates strong financial performance.
Reaffirmation of 2026 financial guidance reflects confidence in growth.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+94%
120-day peak, hindsight
Typical move
3.3%
average across 5 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
BPS804
Phase 2 · Hypophosphatasia
Full Press Release Details
Second quarter total revenue of $214 million, Crysvita ® revenue of $156 million and Dojolvi ® revenue of $27 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D and SG&A expenses to be flat to slightly down versus 2025; remain on path
Frequently Asked Questions
What was Ultragenyx's total revenue for Q2 2026?
Ultragenyx reported a total revenue of $214 million for Q2 2026.
How much revenue did Crysvita® generate in Q2 2026?
Crysvita® generated $156 million in revenue during Q2 2026.
What is Ultragenyx's financial guidance for 2026?
Ultragenyx reaffirmed its financial guidance for 2026, expecting total revenue of $730 million to $760 million.
What are the expected R&D and SG&A expenses for 2026?
Ultragenyx anticipates that combined R&D and SG&A expenses will be flat or slightly down compared to 2025.